Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pascal Soriot

AstraZeneca To Invest $50 Bn In The US As Tariff Threat Looms

British pharmaceutical giant AstraZeneca said Tuesday it would invest $50 billion in the United States by 2030 amid Donald Trump's threats to impose tariffs on the sector.

International Business Times · Jul 22, 2025

AstraZeneca CEO Pascal Soriot on why he’s building in the U.S.: ‘Europe is losing ground’

Also: All the news and watercooler chat from Fortune.

Fortune · Jul 22, 2025

AstraZeneca to invest $50bn in US by 2030 amid Trump tariff threats

UK company to fund new drug manufacturing facility in Virginia and expand R&D facilities around US

The Guardian - UK · Jul 22, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Rachel Reeves vows to stick to fiscal rules and declines to rule out wealth tax – as it happened

Rolling coverage of the latest economic and financial news, as chancellor Rachel Reeves testifies to House of Lords economic affairs committee

The Guardian - UK · Jul 22, 2025

If AstraZeneca goes to the US, it will be a major blow for London and Labour

Move would deprive LSE of its biggest star and could topple a key pillar of the government’s industrial strategy

The Guardian - UK · Jul 2, 2025

Fears over £160bn blow to London’s stock market as AstraZeneca considers listing move to US

CEO Pascal Soriot has not hidden his annoyance at taxes and regulations the pharmaceutical firm have to navigate

The Independent UK · Jul 2, 2025

AstraZeneca boss ‘wants to shift stock market listing to US’

Report claims CEO Pascal Soriot talked in private about moving UK’s most valuable listed company and considered shifting its domicile

The Guardian - UK · Jul 1, 2025

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca Moves Some Production To US Amid Tariff Threat

British pharmaceutical giant AstraZeneca announced Tuesday that it has begun moving some of its European production to the United States, ahead of President Donald Trump's possible tariffs on the sector.

International Business Times · Apr 29, 2025

Drugmaker AstraZeneca shifts more production to US amid Trump tariffs

UK and rest of Europe risk losing out to US and China unless they ramp up spending on new medicines, says CEO Pascal Soriot

The Guardian - UK · Apr 29, 2025

AstraZeneca plots US expansion despite Trump tariff threat

The drug maker said it is ‘firmly committed to investing and growing in the US’ amid potential import tariffs on the pharmaceutical industry.

Evening Standard · Apr 29, 2025

Drug firm bosses call for price increases in Europe amid tariff uncertainty

The boss of AstraZeneca said Europe should increase spending on health treatment in line with recent commitments on defence.

Evening Standard · Apr 23, 2025

China, America and pay inject drama into AstraZeneca’s AGM

The boss’s bonus is an annual debating point at Britain’s biggest company. But that’s not the only issue this year

The Guardian - UK · Apr 6, 2025

GSK could double CEO Emma Walmsley's pay to $27 million

The British pharma giant said Emma Walmsley's current pay could put off candidates for her eventual successor.

Fortune · Feb 28, 2025

AstraZeneca boss takes home £15m pay packet after profits rise

The Cambridge-based pharmaceutical company behind a variety of medicines paid its chief executive Pascal Soriot £14.7 million in 2024.

Evening Standard · Feb 18, 2025

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK · Feb 8, 2025

AstraZeneca, Whitehall, and a failed £450m deal for the next generation in vaccines. What went wrong?

When the pharma firm cancelled plans for a major expansion of its Merseyside plant last month, there was no shortage of questions – or blame – over responsibility

The Independent UK · Feb 7, 2025

Inside AstraZeneca’s abandoned UK vaccine plant deal as Labour and Tories face questions over £450m collapse

AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl Matchett and Whitehall editor Kate Devlin question why it fell through

The Independent UK · Feb 6, 2025

AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine site

Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision.

The Guardian - UK · Feb 3, 2025

AstraZeneca’s £450m Speke U-turn looks terrible for a pro-growth government

It seems bizarre that ministers and UK’s largest company cannot complete investment in vital life sciences sector

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK · Jan 12, 2025

From the Beatles to biologics – how Liverpool became a life science hotspot

The city has a long history with tropical medicine and is now home to one of the largest biotech clusters in Europe

Fortune · Dec 11, 2024

Billonaire calls for CEOs to be paid like footballers, despite earning double them

Lord Michael Spencer says U.K. CEOs need to earn more to retain the best talent.

The Guardian - UK · Nov 12, 2024

AstraZeneca’s numbers are good but trouble in China could drag it down

Profits beat forecasts but a 17% fall in share price since executives were detained by Beijing may be hard to shake

The Guardian - UK · Nov 12, 2024

AstraZeneca says it takes China investigation ‘very seriously’

UK’s biggest pharmaceutical company ‘committed to China’ as it raises 2024 profit forecast and announces $3.5bn US investment

The Guardian - UK · Nov 12, 2024

UK grocery inflation picks up to 2.3%; unemployment rises while regular wage growth slows – as it happened

Consumers started their Christmas shopping early, Kantar says; UK jobless rate rises to 4.3% while wage growth excluding bonuses is at a two-year low

Evening Standard · Nov 12, 2024

FTSE 100 Live 12 November: Vodafone and AstraZeneca results fail to revive shares, Metro Bank fined £16m

Cracks are appearing in the labour market after the unemployment rate today rose to 4.3%.

Barchart · Aug 14, 2024

As Radiotherapy Redefines Cancer Care, Here's the Stock to Buy Near 52-Week Highs

A new generation of radiotherapies are redefining cancer care, offering the potential for a more powerful treatment with fewer side effects. It could become a mainstream therapy for the big "traditional" cancers that make the disease the leading cause of death worldwide, which is why Morgan Stanley forecast the radiopharma…

1 2 3 4

Coverage From

People

Margherita Della Valle

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Office for National Statistics

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.